IGNITE
7 evidence topics · 2 sources
Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using IPCG progression-free survival as the primary endpoint
Primary and secondary endpoints
Validation as a surrogate for survival
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
The retained publication describes an ongoing, open-label randomized trial with blinded independent review of progression-free survival. It does not provide comparative efficacy or safety results. Progression-free survival is the primary endpoint; overall survival is a secondary endpoint.